危重症患者接受头孢他啶/阿维巴坦治疗后产KPC肺炎克雷伯菌的定植
研究纳入2020年1月至2021年1月接受头孢他啶/阿维巴坦(CAZ-AVI)方案治疗的90例成人患者,评估产KPC肺炎克雷伯菌(KPC-Kp)对CAZ-AVI耐药的发生。6例(6.6%)患者在CAZ-AVI暴露后因耐药KPC-Kp发生感染,3例(3.3%)在直肠出现CAZ-AVI耐药。基因分析显示耐药与blaKPC-3突变(blaKPC-31、blaKPC-53、blaKPC-89和blaKPC-130)相关。
要点
- 90例接受CAZ-AVI方案治疗患者中,6例(6.6%)在暴露后因耐药KPC-Kp发生感染。
- 3例(3.3%)患者在直肠出现CAZ-AVI耐药,直肠耐药在中位32天(IQR 9-35)后出现。
- 耐药与突变型blaKPC-3(blaKPC-31、blaKPC-53、blaKPC-89和blaKPC-130)相关。
核心结论
- 抗菌药物暴露在CAZ-AVI治疗患者的血液和呼吸道中诱导CAZ-AVI耐药发生的比例高于直肠(6.7% vs. 3.3%)。
- 基因组分析显示耐药与突变型blaKPC-3变异体相关。
研究设计与样本
- 研究纳入2020年1月至2021年1月接受CAZ-AVI方案治疗的成人患者。
- 对临床样本和直肠拭子中收集的产碳青霉烯酶分离株评估抗菌药物暴露后CAZ-AVI耐药的发生。
- 对发生CAZ-AVI耐药的KPC-Kp及亲代敏感株进行基因组特征分析,全基因组测序使用Illumina iSeq100平台,分析抗菌药物耐药基因、质粒和孔蛋白序列。
主要发现
- 共纳入90例接受CAZ-AVI方案治疗的患者,其中62.2%(56/90)在CAZ-AVI方案治疗前已定植产KPC菌,6.6%在治疗期间获得定植。
- 6例(6.6%)患者在CAZ-AVI暴露后因耐药KPC-Kp发生感染,其中3例(3.3%)在直肠出现CAZ-AVI耐药。
- 直肠KPC耐药在中位32天(IQR 9-35)治疗后出现,临床标本中在中位30天(IQR 22-40)后出现。
- 遗传分析表明CAZ-AVI耐药的发生与突变型blaKPC-3(blaKPC-31、blaKPC-53、blaKPC-89和blaKPC-130)相关,系统发育分析显示同一患者直肠和临床样本中收集的KPC-Kp之间基因组关系密切。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Ceftazidime-avibactam (CAZ-AVI)-based treatments have been associated with the emergence of resistance in KPC-producing Klebsiella pneumoniae (KPC-Kp) isolates after antimicrobial exposure. Here, we evaluated the CAZ-AVI resistance development in KPC-Kp isolated from patients treated with CAZ-AVI-based therapy. METHODS: We enrolled adult patients treated with CAZ-AVI-based regimens between January 2020 and January 2021. Carbapenemase-producing isolates collected from clinical samples and rectal swabs were evaluated for CAZ-AVI resistance development after antimicrobial exposure. KPC-Kp developing CAZ-AVI resistance and parental susceptible strains were genomically characterized. Whole genome sequencing was performed by using the Illumina iSeq100 platform and genomes were analyzed for antimicrobial-resistance genes, plasmid and porins sequences. RESULTS: We enrolled 90 patients treated with CAZ-AVI-based therapy and 62.2% (56/90) of them were colonized by KPC-producers before CAZ-AVI-based treatment and 6.6% acquired colonization during therapy. Six (6.6%) patients developed infections because of resistant KPC-Kp after CAZ-AVI exposure and 3 (3.3%) of them developed CAZ-AVI resistance in the rectum. Development of resistance among KPC in the rectum occurred after 32 (IQR, 9-35) days of therapy and after 30 (IQR, 22-40) days in clinical specimens. Genetic analysis demonstrated that the development of CAZ-AVI resistance was associated with mutated blaKPC-3 (blaKPC-31, blaKPC-53, blaKPC-89, and blaKPC-130) and phylogenetic analysis demonstrated a close genomic relationship between KCP-Kp collected from rectum and clinical samples of the same patient. DISCUSSION: Antimicrobial exposure induce a higher incidence of CAZ-AVI resistance development in the blood and respiratory tract than in the rectum (6.7% vs. 3.3%) of CAZ-AVI-treated patients and genome analysis showed that resistance was associated with mutated blaKPC-3 variants.
引用
- Gaibani P, Bovo F, Bussini L, et al. Colonization by ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae following therapy in critically ill patients. Clin Microbiol Infect. 2023. PMID: 36716999. doi:10.1016/j.cmi.2023.01.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。